Pharmacogenetics: An opportunity for a safer and more efficient pharmacotherapy

Journal of Internal Medicine

Volumn 250, Issue 3, 2001, Pages 186-200

  Ingelman Sundberg, M ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Adverse drug reactions; Drug receptors; Drug transporters; Genetic polymorphism; Poor metabolisers; Ultrarapid metabolism

Indexed keywords

ACYLTRANSFERASE; ALCOHOL DEHYDROGENASE; ALDEHYDE DEHYDROGENASE; BETA 2 ADRENERGIC RECEPTOR; CODEINE; CYTOCHROME P450 1A1; CYTOCHROME P450 2A6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; DIHYDROPYRIMIDINE DEHYDROGENASE; DRUG METABOLIZING ENZYME; GLUTATHIONE TRANSFERASE; GLUTATHIONE TRANSFERASE M1; GLYCOPROTEIN P; LIPOXYGENASE; LIPOXYGENASE A; LOSARTAN; MORPHINE; MU OPIATE RECEPTOR; OMEPRAZOLE; PERPHENAZINE; PROGUANIL; SEROTONIN 2A RECEPTOR; SEROTONIN TRANSPORTER; THIOPURINE METHYLTRANSFERASE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; WARFARIN;

ALLELE; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG TARGETING; ENZYME ACTIVITY; GENE DUPLICATION; GENE EXPRESSION; GENE FREQUENCY; GENE LOCUS; GENE MUTATION; GENE SEQUENCE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; LONG QT SYNDROME; MISSENSE MUTATION; PH; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW;

CYTOCHROME P-450 ENZYME SYSTEM; FORECASTING; HUMANS; MUTATION; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS; PHARMACOKINETICS;

EID: 0035721949     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2796.2001.00879.x     Document Type: Review

References (70)

1. Single-nucleotide polymorphisms in the public domain: How useful are they?
2. Polymorphic human cytochrome P450 enzymes: An opportunity for individualized drug treatment
3. Pharmacogenomics: Translating functional genomics into rational therapeutics
4. Pharmacogenetics and adverse drug reactions
5. Clinical application of pharmacogenetics
6. Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies
7. Reply
8. Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality
9. Adverse drug reactions as a cause of admission to an acute medical assessment unit: A pilot study
10. Adverse drug reactions as a cause for admission to a clinic of internal medicine
11. Getting the right drug into the right patient
12. Identification of functionally important MDR1 variant alleles among African-American and caucasian subjects
13. Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo
14. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects
15. A family of drug transporters: The multidrug resistance-associated proteins
16. Screening a large reference sample to identify very low frequency sequence variants: Comparisons between two genes
17. The CYP2E subfamily
18. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis
19. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression
20. The decreased in vivo clearance of CYP2D6 substrates by CYP2D6*10 might be caused not only by the low-expression but also by low affinity of CYP2D6
21. Disposition of perphenazine is related to polymorphic debrisoquin hydroxylation in human beings
22. Omeprazole and CYP2C19 polymorphism: Effects of long-term treatment on gastrin, pepsinogen I, and chromogranin A in patients with acid related disorders
23. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications
24. Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment
25. 10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes
26. Disposition of debrisoquine in Caucasians with different CYP2D6-genotypes including those with multiple genes
27. Frequent occurrence of CYP2D6 gene duplication in Saudi Arabians
28. Characterization of a human glutathione S-transferase mu cluster containing a duplicated GSTM1 gene that causes ultrarapid enzyme activity
29. Genetic polymorphisms in the cytochrome P450 2A6 (CYP2A6) gene: Implications for interindividual differences in nicotine metabolism
30. Duplications and defects in the CYP2A6 gene: Identification, genotyping, and in vivo effects on smoking
31. MPTP, the neurotoxin inducing Parkinson's disease, is a potent competitive inhibitor of human and rat cytochrome P450 isozymes (P450bufI, P450db1) catalyzing debrisoquine 4-hydroxylation
32. Inhibition of debrisoquine hydroxylation with quinidine in subjects with three or more functional CYP2D6 genes
33. Inhibition of cytochrome P450 2A6 increases nicotine's oral bioavailability and decreases smoking
34. Quick onset of severe abdominal pain after codeine in an ultrarapid metabolizer of debrisoquine
35. Pharmacogenetics and cancer chemotherapy
36. Why study metabolic susceptibility to cancer?
37. N-acetyltransferases: Pharmacogenetics and clinical consequences of polymorphic drug metabolism
38. Thiopurine pharmacogenetics: Clinical and molecular studies of thiopurine methyltransferase
39. Genetic polymorphism of thiopurine S-methyltransferase: Molecular mechanisms and clinical importance
40. The role of innovation in drug development
41. Pharmacogenetics of beta-1- and beta-2-adrenergic receptors
42. Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness
43. Pharmacogenetics and the practice of medicine
44. Systematic screening for mutations in the human serotonin-2A (5-HT2A) receptor gene: Identification of two naturally occurring receptor variants and association analysis in schizophrenia
45. No evidence for association of serotonin-2A receptor variant (102T/C) with schizophrenia or clozapine response in a Chinese population
46. Analysis of a structural polymorphism in the 5-HT2A receptor and clinical response to clozapine
47. Pharmacogenetics for the individualization of psychiatric treatment
48. Opiates, opioids and addiction
49. mu-Opioid receptor knockout mice do not self-administer alcohol
50. A single-nucleotide polymorphic mutation in the human mu-opioid receptor severely impairs receptor signaling
51. Ion channels - Basic science and clinical disease
52. MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia
53. A common polymorphism associated with antibiotic-induced cardiac arrhythmia
54. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment
55. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels
56. Role of the deletion of polymorphism of the angiotensin converting enzyme gene in the progression and therapeutic responsiveness of IgA nephropathy
57. Association between angiotensin-converting-enzyme gene polymorphism and failure of renoprotective therapy
58. Influence of the angiotensin II type 1 receptor gene polymorphism on the effects of perindopril and nitrendipine on arterial stiffness in hypertensive individuals
59. Effect of the insertion/deletion polymorphism of the angiotensin-converting enzyme gene on response to angiotensin-converting enzyme inhibitors in patients with heart failure
60. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis
61. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families
62. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease
63. Cytochrome P4502C9: An enzyme of major importance in human drug metabolism
64. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin
65. Genetic and molecular basis of cardiac arrhythmias: Impact on clinical management parts I and II
66. Ten percent of North Spanish individuals carry duplicated or triplicated CYP2D6 genes associated with ultrarapid metabolism of debrisoquine
67. CYP2D6 genotypes in a Japanese population: Low frequencies of CYP2D6 gene duplication but high frequency of CYP2D6*10
68. Occurrence of CYP2D6 gene duplication in Hong Kong Chinese
69. Polymorphic human cytochrome P450 enzymes: An opportunity for individualized drug treatment
70. Duplication, multiduplication, and amplification of genes encoding drug-metabolizing enzymes: Evolutionary, toxicological, and clinical pharmacological aspects